The INK4a-ARF locus encodes two tumor suppressor proteins involved in cell-cycle regulation, p16 INK4a INK4a gene inactivation in the development of colon carcinoma. They suggest that the methylation profile of specific genes, in particular p14 ARF and p16 INK4a , might be related to biologically distinct subsets of colon carcinomas and possibly to different tumorigenic pathways. (Lab Invest 2001, 81:217-229).
B
oth the p53 and the pRb pathways of cell-cycle control appear to be deregulated during colon carcinogenesis, contributing to uncontrolled cell proliferation. Wild-type p53 activates transcription of the cyclin-dependent kinase inhibitor p21 WAF1 gene, whose encoded protein is capable of inactivating cyclin D1-CDK4 complexes and thereby preventing cells from entering S phase (El-Deiry et al, 1993) . In tumor cells, the lack of a functional p53 protein, often caused by a mutation of one p53 allele and deletion of the wild-type allele, results in reduced p21 WAF1 protein levels and consequently cell-cycle activation. A p53 gene alteration occurs in roughly 50% of colon carcinomas (Fearon and Vogelstein, 1990) . The antiproliferative effect of p53 may also be abrogated by the Mdm2 protein, which inhibits the transactivating activity of p53 (Momand et al, 1992) and catalyzes p53 degradation via ubiquination (Haupt et al, 1997) . Active (hypophosphorylated) pRb protein is capable of complexing with and inactivating the E2F transcription factor, preventing exit from G1 phase. Mutations of the Rb gene or phosphorylation of the pRb protein by cyclin D-CDK4/6 complexes result in the liberation and activation of E2F, which promotes entry into the S phase and activates cell proliferation (Sherr, 1996; Weinberg, 1995) .
The INK4a-ARF locus, situated at 9p21, contains two tumor suppressor genes, p16
INK4a (CDKN2A, MTS1) and p14 ARF (p19 ARF in the mouse), characterized by two distinct promoters and first exons spliced to a common exon 2 in different reading frames Quelle et al, 1995; Serrano et al, 1993; Stone et al, 1995) . The two encoded proteins, which are totally unrelated in terms of amino acid sequence, contribute to cell-cycle control via the pRb and the p53 pathways, respectively (Sherr, 1998) . The p16
INK4a gene product is an inhibitor of cyclindependent kinase 4 and 6 (CDK4/6), capable of preventing pRb phosphorylation and thereby blocking a cell in G1 (Cordon-Cardo, 1995; Serrano et al, 1993 Serrano et al, , 1996 Sherr, 1996) . In the absence of a functional p16
INK4a protein, CDK4 binds to cyclin D and phosphorylates pRb, releasing E2F, which stimulates entry into the S phase and contributes to proliferation activation. In human tumors, the p16
INK4a gene is frequently inactivated by homozygous deletions, point mutations (Cairns et al, 1994; Kamb et al, 1994; Okamoto et al, 1994; Spruck et al, 1994) , or de novo methylation of its promoter region (Gonzales-Zulueta et al, 1995; Herman et al, 1995; Merlo et al, 1995) . The p16
INK4a gene is methylated in about 40% of sporadic colon carcinomas (Toyota et al, 1999) . The p14 ARF protein inhibits cell proliferation by blocking Mdm2-mediated degradation of p53 and by neutralizing Mdm2's inhibition of the p53 transactivating activity (Kurokawa et al, 1999; Pomerantz et al, 1998; Prives, 1998; Zhang et al, 1998) . Thus, p14 ARF inactivation is a mechanism to disrupt the p53/p21 pathway, which contributes to uncontrolled proliferation in human neoplasia. Accordingly, p19
ARF null mice develop diverse types of cancer (Kamijo et al, 1997 (Kamijo et al, , 1999 Serrano et al, 1996) , and p14 ARF may be silenced by promoter methylation in cancer cell lines (Robertson and Jones, 1998 
Results
Sixty primary colon carcinoma and normal colon mucosa samples and 8 colon carcinoma cell lines were analyzed for p14 ARF and p16 INK4a promoter methylation by using three different techniques: restriction enzyme-related PCR (REP), methylation-specific PCR (MSP), and bisulfite single-strand conformation polymorphism (BSSCP). The analyses were confirmed by bisulfite genomic sequencing (BGS). The localization of the CpG dinucleotides from the p14 ARF -and p16
INK4a -promoter and exon 1 regions covered by these techniques are indicated in Figure 1 . INK4a was determined in all primary carcinomas by analyzing two microsatellite markers at chromosome 9p21.
p14 ARF Status in Primary Colon Cancer and in Colon Carcinoma Cell Lines
The p14 ARF gene was methylated in 20 of 60 (33%) primary colon carcinomas and was unmethylated with all three methods in the 60 corresponding adjacent tumor-free colon mucosa samples (Table 1) . Methylation was detected by REP, MSP, and BSSCP in nine cases, by REP and BSSCP in eight cases, by REP and MSP in one case, and by REP only in two cases. All cases positive for p14 ARF methylation by BSSCP showed a characteristic additional band (Fig. 2) , which was excised from the BSSCP gel and reamplified by PCR. Direct sequence analysis indicated that almost all CpG dinucleotides present in the analyzed fragment were methylated. By contrast, direct sequencing of the other BSSCP bands showed a fully unmethylated sequence. A CGG (arginine) to TGG (tryptophan) somatic mutation at codon 12 of p14 ARF exon 1␤ was detected by SSCP and confirmed by DNA sequencing in tumor 2888 (Figs. 2 and 3 ). There was no evidence 
p14
ARF and p16 INK4a gene promoter/exon 1 regions analyzed for methylation, derived from GenBank accession numbers AF082338 and X94154. In both diagrams, the start of the coding region is indicated by an asterisk and is defined as position ϩ1. The bent arrows correspond to the previously identified transcription start site of p14 ARF and to two of the putative transcription start sites of p16 INK4a . The short vertical lines correspond to the positions of the CpG dinucleotides analyzed by the different technical approaches. The positions of the restriction sites analyzed by restriction enzyme-related PCR (REP) are indicated by full circles (H, HpaII; K, KspI). The CpG dinucleotides covered by the methylation-specific PCR (MSP) primers are indicated by full arrowheads (f, reverse primer; r, reverse primer). The horizontal brackets delineate the PCR fragments amplified using the primer sets indicated in Table 4 and analyzed by bisulfite single-strand conformation polymorphism (BSSCP) and/or bisulfite genomic sequencing (BGS) (R, S, and T, fragments amplified with the R, S, and T primer sets indicated in Table 4 ). Table 2 ). To evaluate the distribution of methylated CpG dinucleotides within the p14 ARF promoter/exon 1␤ region, one of the amplified bisulfite-modified fragments analyzed by BSSCP was cloned, and individual clones were sequenced. Because the BSSCP patterns of the different PCR runs were identical, we decided to restrict cloning and sequence analysis to one of them, considering it to be representative. We observed some heterogeneity in the methylation pattern from one cell line to another, but the density of methylated CpGs in the analyzed fragments was elevated in all methylated alleles examined (Table 3) . By SSCP analysis of p14 ARF exon 1␤, we found that HCT116 contained an aberrantly migrating band, suggestive of mutation. By DNA sequencing, we identified a single base (guanidine) deletion within codon 33 generating a stop codon at codon 47. The mutation was confirmed by analyzing the sequences of independent BGS clones, which demonstrates that the mutation was present on the unmethylated allele of p14 ARF exon 1␤ (Fig. 3) . No evidence of p14 ARF exon 1␤ mutation was observed in the other seven cell lines. Expression of p14 ARF mRNA was demonstrated by RT-PCR in the four p14 mϪ/Ϫ tumors and in the three p14 mϩ/Ϫ tumors, but was undetectable in the p14 mϩ/ϩ tumor (Fig. 4, Table 2 ). Full-length p14 ARF cDNA from HCT116 was obtained by reverse transcription, cloned, and sequenced. The only sequence obtained corresponded to mutated cDNA, confirming silencing of the wild-type allele by methylation (data not shown).
p16

INK4a Status in Primary Colon Cancer and in Colon Carcinoma Cell Lines
The p16 INK4a gene was methylated in 19 of 60 (32%) primary colon carcinomas and appeared unmethylated with all three methods in the 60 corresponding adjacent tumor-free colon mucosa samples (Table 1) . 
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Methylation was detected by REP, MSP, and BSSCP in 11 cases, by REP and MSP in 7 cases, and by REP only in 1 case (Fig. 2) . In all cases that were methylation-positive by BSSCP, a characteristic additional band was observed, which was cut from the BSSCP gel and reamplified by PCR. By direct sequencing, we found that almost all CpG dinucleotides present in the analyzed fragment were methylated. All cases were analyzed for p16
INK4a point mutations by SSCP. No tumor-specific mutation of p16
INK4a exons 1, 2, or 3 was found in the 60 primary colon carcinomas.
Of the eight colon carcinoma cell lines, seven contained a methylated p16
INK4a gene, as demonstrated by REP, MSP, and BSSCP ( Fig. 4) and confirmed by BGS analysis. MSP and BGS analyses showed that the p16
INK4a gene was homozygously methylated (p16 mϩ/ϩ ) in five cell lines (HT29, SW480, Isreco1, Cosut, and Colo205), heterozygously methylated (p16 mϩ/Ϫ ) in two cell lines (HCT116 and ALTI), and unmethylated (p16 mϪ/Ϫ ) in one cell line (EE39c) (Fig. 4 , Table 2 ). In HCT116, we observed an additional band by SSCP analysis of p16
INK4a exon 1. By direct sequencing of this band, we found the single-base insertion within codon 23 previously described (Okamoto et al, 1994) and found it to be on the unmethylated p16
INK4a allele of HCT116 (Myöhänen et al, 1998 ). There was no evidence of p16
INK4a exon 1, 2, or 3 mutation in the seven other tumor cell lines. By RT-PCR, p16
INK4a mRNA was detected in the p16 mϪ/Ϫ tumor, as well as in both p16 mϩ/Ϫ tumors, but was undetectable in the five p16 mϩ/ϩ tumors (Fig. 4 , Table 2 ).
p14 ARF /p16 INK4a Allele Loss in Primary Colon Carcinomas
All 60 tumors and corresponding nonneoplastic mucosa samples were analyzed for allele loss at 9p21 using the D9S1748 and D9S942 microsatellite markers. Of the 57 tumors informative for at least one of the polymorphisms, 11 (19%) showed a deletion of one p14 ARF /p16 INK4a allele. Six of these tumors were p16
INK4a methylated, whereas none of them were p14 ARF methylated. In tumor 2888, which contains a p14 ARF exon 1␤ mutation, the wild-type allele was also deleted.
hMLH1 Gene Methylation in Colon Cancer
An aberrantly migrating band was observed by BSSCP analysis of the hMLH1 promoter region in five primary colon carcinomas (Fig. 5 ) and in one of eight colon cancer cell lines: HT29 (Table 2 ). The aberrant bands were cut from BSSCP gels and reamplified by PCR. Direct sequencing showed that almost all CpG dinucleotides present in the analyzed fragment were methylated.
p53 Expression in Primary Colon Carcinomas
The expression of p53 was analyzed by immunohistochemistry in 59 primary colon carcinomas. Twentyfive carcinomas were considered as positive for p53 expression. In 18 of them, p53 staining was strongly positive in the nucleus of 70% to 100% of the tumor cells. In seven other tumors, there was a nuclear expression of p53 in 40% to 50% of the tumor cells. In the remaining 34 carcinomas, which were considered negative for p53 expression, there was no or only sparse nuclear staining for p53 (less than 1% of tumor cells). 
Discussion
The p14 ARF tumor suppressor gene product activates and stabilizes p53 by interacting directly with Mdm2, resulting in cell-cycle arrest (Sherr, 1998) . It has been demonstrated that the amino-terminal portion of p14 ARF , comprising the 64 amino-acids encoded by alleles. By BSSCP, the position of the four bands corresponding to an unmethylated allele is indicated by empty arrowheads. The additional bands reflect the presence of methylated alleles with different methylation patterns (see Table 3 ).
Burri et al
exon 1␤, is sufficient to induce cell-cycle arrest Zhang et al, 1998) . In human tumors, however, no tumor-specific point mutations of p14 ARF exon 1␤ have been reported thus far (Robertson and Jones, 1998; Ruas and Peters, 1998; Sherr, 1998) .
In this study, we describe the two first-point mutations affecting the first exon of the p14 ARF gene. In the HCT116 colon cancer cell line, we identified a single base deletion within codon 33 resulting in a 47 amino acid truncated protein composed of the correct first 32 amino acids from p14 ARF and of 15 incorrect amino acids. A second mutation, an arginine to tryptophan substitution at codon 12 of p14 ARF exon 1␤, was identified in a primary colon carcinoma (Case 2888), indicating that point mutations in this region do not simply represent in vitro cell culture artifacts. p14 ARF localizes to the nucleolus via a C-terminal domain, and mutations of p14 ARF exon 2 disrupt p14 ARF' s nucleolar localization and its ability to stabilize p53 (Zhang and Xiong, 1999) . Therefore, it is likely that the former mutation, which amputates two thirds of the C-terminal part of p14 ARF , compromises both nucleolar localization and p14 ARF -dependent growth arrest. On the other hand, given that one of the Mdm2 binding sites is localized within the 15 N-terminal amino acids of p14 ARF (Midgley et al, 2000; Weber et al, 2000) , it is likely that the codon 12 mutation, which changes a positively charged arginine into a hydrophobe tryptophan in a conserved region, abrogates Mdm2 binding and cell-cycle arrest. We are currently investigating how these mutations affect the activity of p14 ARF on cell-cycle regulation. It should be emphasized that for both identified p14 ARF mutations the wild-type p14 ARF allele was inactivated, by methylation in HCT116 and by deletion (loss of heterozygosity) in tumor 2888, which supports the hypothesis that these mutations are of functional relevance. A similar observation of mutation on one allele and methylation of the wild-type allele has been reported (Myöhänen et al, 1998) INK4a genes in eight colon carcinoma cell lines, we observed that for both genes, methylation of both alleles was required to completely silence transcription. Similar observations have been reported recently on colon cancer cell lines (Robertson and Jones, 1998) and in primary colon carcinomas (Esteller et al, 2000) . Altogether, the present and previously reported data strongly suggest that methylation silencing of the p14 ARF gene, as for the p16
INK4a gene, is frequently involved in the pathogenesis of colon carcinoma. In accordance with Esteller et al (Esteller et al, 2000) , we found no correlation between p14 ARF and p16 INK4a methylation in colon cancer, which is intriguing given the proximity of the two genes. We previously observed that one third of human B-cell lymphomas contained methylated p16
INK4a genes, whereas the p14 ARF gene was never methylated in these tumors (Baur et al, 1999) . These observations suggest that de novo methylation during tumorigenesis results from independent and possibly sequence-specific mechanisms. In addition, these observations are in agreement with the hypothesis that the methylation profile of different genes or CpG islands might be a tumor type-specific phenomenon (Liang et al, 1998; Melki et al, 1999) . Using BGS, we found that several p14 ARF methylation patterns may coexist from one allele to another in the same colon cancer cell line. This has already been reported in different tumor types for other genes, such as p16
INK4a (Baur et al, 1999; Melki et al, 1999) , Rb (Stirzaker et al, 1997) , p15
INK4b (Melki et al, 1999) , and E-cadherin (Melki et al, 1999) , but remains unexplained. Methylation of both p14 ARF and p16
INK4a
genes was significantly more frequent in right-sided than in left-sided colon carcinomas (p ϭ 0.02), as observed for hMLH1 methylation (Toyota et al, 1999) , suggesting that general de novo methylation might be related to localization in the colon. The fact that the p14 ARF gene was significantly more often methylated in well-differentiated adenocarcinomas (p ϭ 0.005) and, conversely, that p16
INK4a methylation was more frequent in poorly differentiated carcinomas (p ϭ 0.002), suggests that a given methylation profile might not only reflect the histogenesis of a tumor but might also define biologically distinct subsets and possibly different tumorigenic pathways within a given tumor category. It has been suggested that in colon carcinoma, virtually all cancer-specific methylation events (called type C methylation) occur in a distinct subset of tumors, thereby defining a new phenotype, the CpG island methylator phenotype (CIMP) (Toyota et al, 1999) . In the proposed concept, the CIMPϩ colon carcinomas would be characterized by the simultaneous methylation of multiple tumor-suppressor genes such as p16 INK4a and by the induction of mismatch repair deficiency through hMLH1 gene inactivation (Toyota et al, 1999) . The remaining nontumor-specific methylation events (called type A, for aging-specific methylation) detected in colon cancer would be related to incremental hypermethylation in the normal colon as an age-related phenomenon (Toyota et al, 1999) . In agreement with the CIMP concept, we found that p16
INK4a gene methylation (a) occurred in about one third of primary colon carcinomas, more often in right-sided tumors, (b) was not age-dependent, and (c) was statistically correlated to hMLH1 methylation (p ϭ 0.03). As with p16
INK4a methylation, p14
ARF methylation fulfilled the criteria of type C, but not type A, methylation, in that it was not detectable in normal colon mucosa and was not associated with patient's age. In addition, contrary to p16
INK4a methylation, p14 ARF methylation was not associated with hMLH1 methylation. These observations suggest that p14 ARF and p16 INK4a may be meth- 
ϩ, methylated; Ϫ, unmethylated; H, Hpall site analyzed by restriction enzyme-related PCR (REP); K, Kspl site analyzed by REP. * A bisulfite-modified 255-bp fragment from p14 ARF promoter/exon 1␤ region containing 27 CpG dinucleotides (numbered 1-27) was amplified by PCR, cloned, and sequenced. The CpG dinucleotides inside the p14 ARF coding sequence are indicated in bold. The CpG dinucleotide covered by the forward primer in methylation-specific PCR (MSP)-analysis is underlined by small circles. The methylation status of each CpG is indicated.
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ylated through distinct mechanisms and that there are at least two cancer-specific methylation pathways in colon cancer. As a consequence, the notion resulting from the CIMP concept that all tumor-specific methylation events result from a unique pathway and occur in parallel in colon cancer is not consistent with the present findings.
The interaction between p14 ARF and Mdm2 blocks Mdm2-mediated degradation of p53, and neutralizes Mdm2's inhibition of p53 transactivating activity (Kurokawa et al, 1999; Pomerantz et al, 1998; Prives, 1998; Zhang et al, 1998) . In addition, the p14 ARF protein interacts with p53 on chromatin, but there is no direct evidence that p14 ARF plays a physiological role as a p53 coactivator (Kamijo et al, 1998; Sherr, 1998) . In human tumor cell lines, there is an inverse correlation between p14 ARF expression and p53 function (Stott et al, 1998) . In agreement with this observation, we found an inverse statistical correlation between p53 immunohistochemical expression, which generally reflects p53 mutation (Baas et al, 1994; Costa et al, 1995) , and p14 ARF methylation. Esteller et al (2000) observed that p14 ARF methylation was slightly more frequently observed in colon carcinomas with wildtype p53 compared with p53-mutated tumors, although this difference was not statistically significant. It is well established that p53 protein overexpression by immunohistochemistry may be found in p53 wildtype tumors as a result of alternative mechanisms leading to p53 stabilization (Baas et al, 1994; Costa et al, 1995) . One of the factors contributing to p53 stabilization in p53 wild-type tumors might be stabilization of p53 via expression of p14 ARF . This would explain why we observed a statistically significant association between the presence of unmethylated p14 ARF and p53 overexpression and why comparing the presence of unmethylated p14 ARF and p53 mutations did not result in a statistically significant correlation (Esteller et al, 2000) . In addition to the fact that p14 ARF activates p53, it has been suggested that, inversely, p53 might negatively regulate p14 ARF expression in a feedback loop (Stott et al, 1998) . Given that wild-type p53 down-regulates the activity of some CpG-rich promoters by binding Sp1 consensus sites and that p53 mutants lose this repressive effect (Bargonetti et al, 1997) , it is possible that p53 contributes to p14 ARF inactivation (methylation) by interacting with the Sp1 sites of the p14 ARF promoter (Robertson and Jones, 1998) . Because occupied Sp1 sites within CpG islands protect them from de novo methylation (Brandeis et al, 1994; Macleod et al, 1994) , the putative binding of wild-type p53 within the promoter of p14 ARF might abolish the protective effect of Sp1-bound elements, leading to methylation. This hypothesis should be verified by determining whether or not p53 interacts with the p14 ARF promoter and whether this interaction influences p14 ARF methylation. In conclusion, this study shows that (a) rare tumorspecific mutations within p14 ARF exon 1␤ may occur in colon cancer, (b) the p14 ARF and p16 INK4a genes are frequently but independently methylated in colon cancer, which underlines the complexity of the mechanisms leading to de novo methylation in cancer, and (c) the methylation profile of the p14 ARF and p16
INK4a genes might define biologically distinct subsets of colon carcinoma.
Materials and Methods
Primary Tumor Samples and Colon Cancer Cell Lines
Primary Tumors. Samples from 60 primary colorectal adenocarcinomas and corresponding adjacent normal colon mucosa were obtained from surgical resections of colon cancers patients consecutively operated on between 1997 and 1998 at the Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland. The average age of the patients was 69.9 years (range, 37-89 yr). There were 26 females and 34 males. The tumor was localized in the right colon (caecum, ascending) in 26 cases, in the transverse colon in 1 case, and in the left colon (descending, sigmoid, rectum) in 33 cases. Tumors were graded and staged on routinely processed, formalin-fixed and paraffin-embedded tissue samples. According to the tumor node metastasis (TNM) staging system, there were 3 pT1, 7 pT2, 32 pT3, and 17 pT4 tumors. One case could not be staged because of inadequate sampling. Sixteen tumors were well differentiated, 33 moderately differentiated, and 11 poorly differentiated adenocarcinomas. The immunohistochemical expression of p53 was examined on formalin-fixed, paraffinembedded sections on 2 different tumor samples in 59 cases. Tumor and nontumor tissue samples were immediately frozen in liquid nitrogen and stored at Ϫ70°C until DNA extraction. Hematoxylin-and eosinstained (H&E) sections of the frozen specimens were examined to verify representativity.
Colon Cancer Cell Lines. Frozen pellets from 8 colon carcinoma cell lines, HT29, HCT116, SW480, ALTI, Isreco1, EE39c, Cosut, and Colo205, were kindly provided by the laboratory of Dr. Bernard Sordat (Institut Suisse de Recherche Expérimentale sur le Cancer, Epalinges, Switzerland).
Nucleic Acid Isolation
Genomic DNA was extracted from ten 25-m-thick tumor and normal tissue sections and from the cell methylated CpG dinucleotides present in a given DNA fragment. Aberrant bands indicative of methylation, as well as bands corresponding to normal patterns, were excised from the BSSCP gels, reamplified by PCR using the same methyl-independent primers as for BSSCP (Table 4 , R-U), and directly sequenced. In addition, to assess the proportion of methylated and unmethylated alleles in tumor cell lines, the PCR products analyzed by BSSCP were cloned into a pGEM-T vector according to the manufacturer's protocol (Promega, Madison Wisconsin). Ten to twenty independent clones were reamplified and screened by BSSCP . At least two clones of each observed BSSCP pattern were sequenced.
Immunohistochemical Analysis of p53 Expression
The expression of p53 was examined by immunohistochemistry using the peroxidase-antiperoxidase (PAP) technique described previously (Chaubert et al, 1994) . The anti-p53 monoclonal antibody used (Clone DO7, 1:500; Dako Diagnostics, Zug, Switzerland) recognizes both wild-type and mutated forms of p53. Tumors containing more than 40% p53 immunostained nuclei were considered to be positive for p53 protein expression.
Statistical Analysis
The association between p14 ARF and p16 INK4a methylation and the correlation between p14 ARF /p16
INK4a methylation and different parameters was evaluated by Fisher's exact test. A p value Ͻ 0.05 was considered as significant.
